A time-to-event analysis of the exposure–response relationship for bezlotoxumab concentrations and CDI recurrence
Author:
Funder
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology
Link
http://link.springer.com/content/pdf/10.1007/s10928-019-09660-5.pdf
Reference23 articles.
1. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353(23):2433–2441. https://doi.org/10.1056/NEJMoa051590
2. Rupnik M, Wilcox MH, Gerding DN (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7(7):526–536. https://doi.org/10.1038/nrmicro2164
3. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM, Polymer Alternative for CDI Treatment (PACT) investigators, (2014) Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59(3):345–354. https://doi.org/10.1093/cid/ciu313
4. Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Héguy A, Nault V, Valiquette L (2016) Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis 62(5):574–580. https://doi.org/10.1093/cid/civ958
5. Merck Sharp & Dohme Corp. Whitehouse Station, NJ, USA (2016) Zinplava (bezlotoxumab) prescribing information
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review;World Journal of Gastrointestinal Pharmacology and Therapeutics;2024-09-05
2. Predicted Bezlotoxumab Exposure in Patients Who Have Received a Hematopoietic Stem Cell Transplant;Clinical Therapeutics;2023-04
3. The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021;Antibiotics;2022-09-07
4. Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application;CPT: Pharmacometrics & Systems Pharmacology;2022-04-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3